Skip to content

Clinical efficacy of Chushi Pixuan Ointment in the topical treatment of tinea pedis

Clinical efficacy of Chushi Pixuan Ointment in the topical treatment of tinea pedis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000013
Enrollment
Unknown
Registered
2024-01-22
Start date
2022-06-20
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tinea pedis

Interventions

Chushi Pixuan Group:Chushi Pixuan Ointment
Naftifine Ketoconazole Group:Naftifine ketoconazole cream

Sponsors

Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1 Age: 18-65 years old; 2 Meet the diagnostic criteria; 3 Those who can complete the test as required and sign the informed consent;

Exclusion criteria

Exclusion criteria: 1 Those who have received systemic antifungal drugs in the last 3 months or topical antifungal drugs in the last 2 weeks; 2 Those who have received long-term treatment with corticosteroids and immunosuppressants; 3 Women who are breastfeeding and pregnant; 4 Those who have received radiotherapy, anti-viral, anti-bacterial, anti-helminthic treatment within the last 2 weeks; 5 Those who are unable to accept and complete the survey as required; 6 Those with co-morbid nail fungal disease, co-morbid bacterial infections such as dengue; 7 Those who have significant abnormalities in the examination of various systems such as blood, liver, kidney and heart; those who have combined serious primary diseases such as cardiovascular, cerebrovascular, hepatic, renal, neurological and haematopoietic systems; and those who are suffering from psychiatric diseases, malignant tumours, diabetes mellitus and autoimmune diseases; 8 Patients who are themselves investigators directly involved in the work of this study; 9 Patients who are allergic to therapeutic drugs; 10 Those with negative laboratory tests for fungi.

Design outcomes

Primary

MeasureTime frame
Efficacy index;Mycological examination;

Secondary

MeasureTime frame
Evaluation of recurrence (including recurrence or reinfection);Mycological efficacy evaluation;Quality of life score;Evaluation of clinical signs and symptoms;

Countries

China

Contacts

Public ContactXinsheng Chen

Guangdong Provincial Hospital of Traditional Chinese Medicine

xinshengchen@sohu.com020-81887233

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026